Scroll for more
events Dec 6, 2017

Healthcare of the future, Medical Innovations

Join Mark Davies, VP Biomedical Informatics at BenevolentAI for a talk on "Disrupting Drug Discovery with AI"


Dec 6, 2017


09:00 AM



Open in Google Maps >>


Overview of the talk

Despite the huge growth of knowledge and information the process of biomedical discovery has not changed for 50 years.  In the modern world, it impossible for humans alone to process all the complex information potentially available to them for the advancement of scientific research.  For example, a new scientific paper is published every 30 seconds and there are thousands of updates to PubMed every day.  Consequently, only a small fraction of globally generated scientific information can form ‘useable’ knowledge.
Mark Davies will present on how AI can offer a solution to this problem and how he believes machine learning technology is changing how new medicines are discovered and developed.  He will also discuss how AI, rather than supplant human intelligence, will, instead, augment it and that such augmentation is indeed essential to solve some of the world’s great scientific challenges, in this case the discovery of new medicines. AI provides experienced scientists with the analytical tools they need to design better compounds faster.



Mark is the VP Biomedical Informatics at BenevolentAI. He has a background in molecular genetics, bioinformatics  (BSc University of Sussex) and computer science (MSc Birkbeck College) and has over 15 years of experience working on biomedical data representation, data analysis and application development. In 2001, he joined the London based biotechnology company Inpharmatica, where he was initially working on mining the output of the Human Genome Projects and eventually moved on to building Chemogenomics systems used by pharmaceutical companies, such as Bayer. Mark moved to the European Bioinformatics Institute (EMBL-EBI) as one of the founding members and technical lead for the ChEMBL resource - the largest open-source SAR database. Mark was also responsible for the successful transition of the SureChEMBL chemical patent system from Digital Science to the EMBL-EBI. Throughout his career Mark has published on how the use of biomedical data and technologies can improve the drug discovery process and enjoys identifying new opportunities this research space.